Lysosomal processing of sulfatide analogs alters target NKT cell specificity and immune responses in cancer

• Published in: The Journal of clinical investigation Vol. 134; no. 4; pp. 1 - 15
• Main Authors: Nishio, Kumiko, Pasquet, Lise, Camara, Kaddy, DiSapio, Julia, Hsu, Kevin S, Kato, Shingo, Bloom, Anja, Richardson, Stewart K, Welsh, Joshua A, Jiang, Tianbo, Jones, Jennifer C, Cardell, Susanna, Watarai, Hiroshi, Terabe, Masaki, Olkhanud, Purevdorj B, Howell, Amy R, Berzofsky, Jay A
• Format: Journal Article
• Language: English
• Published: Ann Arbor American Society for Clinical Investigation 01.02.2024
• Subjects: Antigen processing; Antigens; Arylsulfatase; Bone marrow; Cancer; CD1d antigen; Colon cancer; Cytokines; Galactosylceramide; Immunotherapy; Lung cancer; Lymphocytes; Lymphocytes T; Major histocompatibility complex; Metastases; Metastasis; Natural killer cells; Structure-function relationships; Sulfatide; Sulfite; T cell receptors; γ-Interferon
• ISSN: 0021-9738; 1558-8238
• DOI: 10.1172/JCI177663

In a structure-function study of sulfatides that typically stimulate type II NKT cells, we made an unexpected discovery. We compared analogs with sphingosine or phytosphingosine chains and 24-carbon acyl chains with 0-1-2 double bonds (C or pC24:0, 24:1, or 24:2). C24:1 and C24:2 sulfatide presented by the CD1d monomer on plastic stimulated type II, not type I, NKT cell hybridomas, as expected. Unexpectedly, when presented by bone marrow-derived DCs (BMDCs), C24:2 reversed specificity to stimulate type I, not type II, NKT cell hybridomas, mimicking the corresponding β-galactosylceramide (βCalCer) without sulfate. C24:2 induced IFN-γ-dependent immunoprotection against CT26 colon cancer lung metastases, skewed the cytokine profile, and activated conventional DC subset 1 cells (cDC1s). This was abrogated by blocking lysosomal processing with bafilomycin A1, or by sulfite blocking of arylsulfatase or deletion of this enyzme that cleaves off sulfate. Thus, C24:2 was unexpectedly processed in BMDCs from a type II to a type I NKT cell-stimulating ligand, promoting tumor immunity. We believe this is the first discovery showing that antigen processing of glycosylceramides alters the specificity for the target cell, reversing the glycolipid's function from stimulating type II NKT cells to stimulating type I NKT cells, thereby introducing protective functional activity in cancer. We also believe our study uncovers a new role for antigen processing that does not involve MHC loading but rather alteration of which type of cell is responding.